Search
Kura Oncology Inc
KURAAdd to Watchlist
9.010USD
-0.300-3.22%
Close 07-31 16:00（ET）Quotes delayed by 15 min
799.86MMarket Cap
LossP/E TTM
More Details of Kura Oncology Inc Company
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
Kura Oncology Inc Info
Ticker SymbolKURA
Company nameKura Oncology Inc
IPO dateNov 05, 2015
CEOWilson (Troy E)
Number of employees192
Security typeOrdinary Share
Fiscal year-endNov 05
Address4930 Directors Place, Suite 500
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18585008800
Websitehttps://www.kuraoncology.com/
Ticker SymbolKURA
IPO dateNov 05, 2015
CEOWilson (Troy E)
Company Executives of Kura Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
149.56K
+6.69%
Ms. Kathleen Ford
Ms. Kathleen Ford
Chief Operating Officer
Chief Operating Officer
52.40K
-4.31%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Lead Independent Director
Lead Independent Director
23.98K
--
Dr. Troy E. Wilson, J.D., Ph.D.
Dr. Troy E. Wilson, J.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
--
--
Ms. Mary T. Szela
Ms. Mary T. Szela
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
--
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Independent Director
Independent Director
--
--
Dr. Teresa Bair, J.D.
Dr. Teresa Bair, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Mr. Brian Powl
Mr. Brian Powl
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
149.56K
+6.69%
Ms. Kathleen Ford
Ms. Kathleen Ford
Chief Operating Officer
Chief Operating Officer
52.40K
-4.31%
Mr. Faheem Hasnain
Mr. Faheem Hasnain
Lead Independent Director
Lead Independent Director
23.98K
--
Dr. Troy E. Wilson, J.D., Ph.D.
Dr. Troy E. Wilson, J.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
--
--
Ms. Mary T. Szela
Ms. Mary T. Szela
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Kura Oncology Inc?
The top five shareholders of Kura Oncology Inc are: Mr. Thomas Robert (Tom) Malley
How many institutions hold shares of Kura Oncology Inc (KURA)?
As of 2026Q1, 457 institutions hold shares of Kura Oncology Inc, with a combined market value of approximately 91.73M, accounting for 103.35% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -26180956.00.